The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (14 analysts) rates it buy, with a mean price target of $173.
NTT (Nippon Telegraph)
9432.T · TSE · JPY · Market cap $12.05T
NTT, Inc.
FAIL · Does not pass the screenAt the last full screen
2026-06-14
Screened 2026-06-14 · the tape above runs as of 23:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 148.00 against the desk's fair-value range, base estimate 215.00, over the last year.
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
NTT (Nippon Telegraph) holds its Markup at $148.00. Consolidating, no directional conviction, held for 30 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 30 days |
| Price at the screen | $148.00 |
| Valuation | 11.74 trailing · 10.17 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | -0.18 |
Five Screens, Shown in Full
Does not pass. Debt ratio 37.2%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 37.16% | Below 33% | Interest-bearing debt is 37.2% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 3.33% | Below 33% | Cash held in interest-bearing accounts and securities is 3.3% of assets, under the one-third limit. | Pass |
| Receivables | 16.24% | Below 49% | Money owed to the company is 16.2% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.81% | Below 5% | Only 0.8% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads AVOID: it trades at roughly a 45% discount to our $215.00 fair value, 9.10% revenue growth.
Fair value range in JPY, drawn from the 2026-06-14 screen. The gold marker is the market price at the same screen. A 45.3% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus None. The average target sits +16% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-06-14 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 10.2x forward earnings, the price already runs ahead of the business. Our fair value sits at $215.00, below where it trades today.
| Forward P/E | 10.2xfairly priced for its growth rate |
| Trailing P/E | 11.7xreasonably valued |
| EPS, trailing | 12.61 |
| EPS, forward | 14.55 |
| Revenue growth | +9.1%steady growth |
| Profit margin | 7.2%thin but positive margins |
| Return on equity | 10.0%a modest return on shareholder capital |
| FCF yield | 84.05% |
| Dividend yield | 365.00% |
| Debt to equity | 1.66a meaningful debt load worth watching |
| Beta | -0.18barely tracks the market's swings |
| 52-week range | 144.30 - 167.20 |
| Market cap | $12.05T |
The risks · The things to watch: its business and earnings are exposed to Japan and to currency swings; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade9432.T trades on TSE (the company is based in Japan). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (13 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (13 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (13 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (13 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (13 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (13 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (13 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (13 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 2%. Our forward projection puts the odds of a 10% gain over the next month near 5%. The street (13 analysts) rates it buy, with a mean price target of $173.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $148.40 | +0.4% | · | $1,004 | +0.4% |
| 2 months | $153.10 | -2.7% | · | $973 | -2.7% |
| 3 months | $153.10 | -2.7% | $2.65 | $991 | -0.9% |
| 6 months | $152.91 | -2.6% | $2.65 | $992 | -0.8% |
| 1 year | $151.91 | -1.9% | $5.30 | $1,016 | +1.6% |
| 2 years | $141.20 | +5.5% | $10.50 | $1,130 | +13.0% |
| 3 years | $150.13 | -0.8% | $15.60 | $1,096 | +9.6% |
| 5 years | $99.23 | +50.2% | $25.00 | $1,754 | +75.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever 9432.T does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.